Chris Hibberd

San Diego, California, United States
Chris has more than 20 years of diagnostics experience in company formation, clinical and business development. Prior to taking the helm of Nucleix, he was CEO and co-founder of Astute Medical. He managed a team and secured funding to support a product pipeline that included the launch of NephroCheck®, the first FDA cleared diagnostic for acute kidney injury risk, until its acquisition by bioMérieux. Prior to Astute Medical, he was SVP of corporate development at Biosite, where he managed business development activities that included cofounding Biosite Discovery and Biosite’s $1.7 billion acquisition by Inverness Medical. Prior to that, he was a manager at The Boston Consulting Group and a development engineer at Albright & Wilson Americas.
Speaking In
3:00 PM - 4:00 PM (PDT)
Wednesday, June 15
 In 2021, cancer diagnostics achieved a long-discussed “Holy Grail” milestone with…